XIV Congresso Nazionale Società Italiana di ... - Salute per tutti

ABSTRACTS XIV Congresso Nazionale Società Italiana di Urologia Oncologicana ed S-100. Il paziente, attualmente, viene solo seguito conTAC ogni anno, non essendo prevista alcuna forma di terapiaadiuvante.Conclusioni: Esistono solo 21 casi descritti in letteratura di questarara neoplasia del testicolo. La maggior parte dei pazientisi presenta con massa testicolare. Solo 2 pazienti su 16 di cui,in letteratura, sia disponibile un follow-up a lungo termine(12,5%), sono morti a causa delle metastasi sviluppatesi dopola chirurgia, in un periodo compreso tra i 5 mesi ed i 14 anni.Nel nostro caso, il paziente era verosimilmente affetto daltumore da circa 15 anni. La TAC toraco-addomino-pelvicaeseguita per stadiazione post operatoria, non ha evidenziatolocalizzazioni secondarie della malattia. Questa forma istologica,caratterizzata da lenta crescita locale, ma potenzialmentedotata di capacità metastatizzante, necessita di trattamentochirurgico locale ed adeguato follow-up postoperatorio, pertutta la vita.Bibliografia:1. Al-Bozom IA, El-Faqih SR, Hassan SH, El-Tiraifi AE, Talic RF.Granulosa Cell Tumor of the Adult Type. A Case Report and Review of theLiterature of a Very Rare Testicular Tumor Archives of Pathology andLaboratory Medicine 124; 10:1525Poster n. 131ACUTE TOXICITY IN 48 PATIENTS WITH PROSTATECANCER TREATED WITH CONFORMAL RADIATION THE-RAPY ± SURGICAL TREATMENTNtreta M. 1 , Bunkheila F. 1 , Guido A. 1 , Rombi B. 1 , CammelliS. 1 , Barbieri E. 11Divisione di Radioterapia,”E. Barbieri” Ospedale S. Orsola, BolognaPurpose: To report our experience with 3D conformal radiotherapyfor prostate cancer.Material and Methods: We reviewed our first 48 patients with prostatecancer. Mean follow-up was 16.5 months (3-36 m). Meanage 69.6years (54-83). Fourteen patients undergone to radicalprostatectomy before 3D conformal radiotherapy and 34 weretreated with only radiation therapy. For the first group T stagewas: pT2apN0M0=3; pT2bpN0M0=1; pT2cpN0M0=3;pT3apN0M0=3; pT3bpN0M0=3; pT3bpN1M0=1. About the secondone T stage was: T1bN0M0=1; T1cN0M0=3; T2aN0M0=4;T2bN0M0=16; T2cN0M0=4; T3aN0M0=5; T3bN0M0=1.Gleason score (GS) 4-6 55,5% and GS 7-8 44,4%. PretreatmentPSA value of 20 ng/ml16%. Thirtyfive pts received androgen ablation therapy 2 to 6months before radiation. 3D conformal radiotherapy was used toallow a smaller amount of rectum and bladder to be in the highdose volume. An 10 and 18 MV linear accelerator was used. Therange of dose recommended for adjuvant radiotherapy was6000cGy-6600cGy and 7000cGy-7400cGy for radical radiotherapytreatment.Results: Symptoms of gastrointestinal and genitourinary toxicityare dose-limiting for pelvic radiotherapy. Existing toxicityregistrations (RTOG) are helpful in defining maximal tolerateddoses.The percentage of volume receveing more than 50Gy(V50) was calculated for the rectum and bladder. The meanV50 was 55% for the bladder and 60% for the rectum. Basedon the RTOG grading (gr) for acute toxicity, there was no gr 3gastrointestinal (GI) and genitourinary (GU) toxicity. Therewere 24 pts with gr0 (50%), 2 pts (4.1%) with gr 1 and 22 pts(45.8%) with gr2 GI toxicity. About the GU toxicity there were21 pts with gr 0 (43.7%), 24 pts with gr 1(50%) and 3 ptswith gr2 (6.2%). With our actual follow-up we have 2 latemorbidities: 2 pts with gr2 GI toxicity.Conclusion: 3D conformal radiotherapy for prostate cancer atour institution has a good toxicity profile and mirrors that discribedin the literature. Longer follow-up is needed to assesslate toxicity and clinical outcome in this series.References:1. Hovdenak N, Karlsdottir A, Sorbye H, Dahl O. Profiles and time courseof acute radiation toxicity symptoms during conformal radiotherapy for cancerof the prostate. Acta Oncol 2003; 42:7412. Michalski JM, Winter K, Purdy J, Perez CA, Ryu JK, Parliament MB,Valicenti RK, Roach M 3rd, Sandler HM, Markoe AM, Cox JD. Toxicity afterthree-dimensional radiotherapy for prostate cancer with RTOG 9406 doselevel IV. Int J Radiat Oncol Biol Phys. 2004; 58:735Comunicazioni n. 132WILMS’ TUMOR: PRESENTATION AND TREATMENTBunkheila F. 1 , Ntreta M. 1 , Guido A. 1 , Rombi B. 1 , CammelliS. 1 , Burnelli R. 2 , Neri S. 1 , Barbieri E. 11Istituto di Radioterapia “E. Barbieri”; 2 Oncologia Pediatrica,Ospedale S. Orsola, BolognaPurpose: Wilms’ tumor is the most common malignant neoplasmof the urinary tract in children. We have managed ourpatients according to CNR/AIEOP 92 protocols and report ourresults herein.Material and Methods: Thirteen patients with Wilms’ tumor betweenJune 1995 and October 2000 were analyzed for distributionsof age, gender, tumor sites, histology and clinical stages.Patients received individualized multimodality treatment baseupon the histology of the tumor and clinicopathologic stage.The treatment included surgery, radiotherapy and chemotherapy.Results: Thirteen patients including 9 girls and 4 boys with themean age of 44.53 months, ranging from 11 months to 11years were studied. Tumour involved right kidney in 6, left in5 and bilateral in 2 patients. Metastatic disease was present atdiagnosis in 3 patients (23%); the most common site of involvementis the lung with 66.6% and the bowel loops with33.3%. Distribution of clinical stage: I= 1 pz (7.6%), II= 1pz(7.6%), III= 4pz (30.7%), IV=5 (38.4%) and V=2 (15.3%).Favorable histology (FH) was diagnosed in 92.3% of patientsand anaplasia diffusa in 7.7%. Recurrence of disease occurredin 3 patients (23%), with lungs (100%) the most frequent siteof relapse. All the patients underwent primary surgery, chemotherapyand radiation therapy. Four patients received a renalfossa irradiation with a mean dose of 1785 cGy consideringthat one of them received 3420 cGy because of the unfavorablehistology. Four patients received whole abdominal irradiationwith mean dose of 1290 cGy and five patients unterwentto a total lung irradiation with a mean dose of 1200 cGy.During and after radiation therapy there was no acute toxicityin the most of patients except two, treated with whole abdominalirradiation, with nausea and vomiting. Four patientsdied after completion of treatment: two for local reccurenceand metastatic disease, one for metastatic disease and the otherone for local reccurence disease.The overall mortality was30.7%: 1 with I stage (7.6%), 2 pts with IV stage (15.3%) and1 with V stage (7.6%).Conclusion: The presentation of Wilms’ tumor at our institutionmirrors that discribed in the literature. Importantly, by followingCNR/AIEOP 1992 protocols we have achieved an outcomeof survival comparable to the “gold standard”.References:1. Pianezza ML, Rubin S, Bass J, Chou S, Pike JG, Leonard MP. Wilms’tumor at the Children’s Hospital of Eastern Ontario. Can J Urol 2004;11:21512. Mahmood A, Ghafoor T, Badsha S. Wilms’ tumor: presentation and treatment.J Coll Physicians Surg Pak 2004; 14:14250Archivio Italiano di Urologia e Andrologia 2004; 76, 3, Supplemento 1